Intellia Therapeutics’ (NTLA) Buy Rating Reaffirmed at Canaccord Genuity Group
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Canaccord Genuity Group in a research note issued on Tuesday,Benzinga reports. They presently have a $90.00 price target on the stock. A number of other research analysts have also recently commented on NTLA. The Goldman Sachs Group reduced […]
More Stories
Legend of Pete Rose Grows Amid Commissioner’s Latest Move
By Donald Laible Pete Rose knew his way around the village of Cooperstown, New York. As a visitor to the...
Microsoft Says 394,000 Windows Computers Infected by Malware Worldwide
By Jack Phillips Tech giant Microsoft warned that nearly 400,000 computers with its Windows operating system were infected with a...
Brock Purdy Lands $265 Million Extension With 49ers
By John Rigolizzo San Francisco 49ers quarterback Brock Purdy is certainly no longer “Mr. Irrelevant” with his signing of a...
DOJ to End Police Reform Agreements, Investigations Into Departments
By Jack Phillips The U.S. Department of Justice (DOJ) has announced it will end its agreements to secure court-approved settlements...
Mortgage Demand Slumps, Rates Rise to Highest Level Since February
By Andrew Moran Demand for mortgages declined last week as interest rates rose to their highest level since February, new...
Congressional Stock Trading Significantly Erodes Public Trust, Study Finds
By City News Service SAN DIEGO—Trading stocks while in office severely erodes the trust of the American people, regardless of...